A Swiss Army knife manufacturer
In de dagelijkse podcast van FC Afkicken bespreken Neal, Bruce en Jaron op donderdag 14 oktober onder meer de overwinning van de documentaire van Arsène Wenger, de potentie van Team USA en de mogelijke winnaar van de Ballon d'Or.(0:00) Intro en documentaire Arsène Wenger(4:05) Team USA met Super Sergiño Dest(11:19) Wat kan Newcastle doen met het 'nieuwe geld'(20:41) Gedecimeerd Dortmund(23:58) Ligue 1 van 20 naar 18 clubs(33:41) Ballon D'OrNeal, Bruce en Jaron verwijzen in de podcast naar:Het draadje op Twitter over NewcastleZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.
England's swashbucklers cut through precisely sod all last night in an underwhelming draw with Hungary. Maybe we need... *more* attackers?Kate, Andy and Jim pick through that throwback performance and celebrate a vital derby win for Scotland in the Faroe Islands. We also wonder how Arsène Wenger can tarnish his legacy even further with more biennial World Cup nonsense and get to some of your dilemmas!Search ‘Football Ramble' on social media to find us, and email us here: email@example.com.***Please take the time to rate and review us on Apple Podcasts or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** See acast.com/privacy for privacy and opt-out information.
Allsvenskans bästa spelare genom tiderna gästar! Om framtidsplanerna! Extremfallet Zlatan! Landslagsbesvikelserna! Karriärens största matcher! Beslutet att avsluta karriären på topp! Relationen till Arsène Wenger! Inlägget 546. Kim Källström dök först upp på Tutto Balutto.
QKWHS - S9 EP6: This Month In The 90's - September 1996It's a brand new QK format this month as we're joined in the studio by Tom Craine to do a deep dive into one specific month during the decade. And seeing as it's the 25th anniversary of September 1996 what better place to start...We discuss all the big news of that month, Wenger's appointment, Wimbledon's amazing run of form, a tepid goal of the month competition and what was going on in the world and with us in general 25 years ago this month... Enjoy! Over on Patreon the Quickly Kevin Fan Club is the place to go to get extended ad free episodes of the main series with exclusive content on a Friday instead of a Monday (yes, a whole 72 hours early!) head on over to www.patreon.com/quicklykevin where you'll also find bonus episodes each month including the chapter by chapter breakdown of the Steve Barnes / Bruce crime novel trilogy. Extra QK Film Cub episodes (most recently a review of Nick Hancock's seminal VHS compilation 'Football Nightmares') and a whole load of new QK Fan Club exclusive episodes coming up in 2021 and into 2022!Thanks,Chris, Josh and Michael.Fan Club: www.patreon.com/quicklykevinTwitter: @quicklykevinInstagram: quicklykevinEmail: firstname.lastname@example.org See acast.com/privacy for privacy and opt-out information.
Cristiano Ronaldo is back in Red, Lukaku 2.0 reacquaints himself to the Bridge fans, and Camavinga marks his Real Madrid debut with a goal. We discuss the “Ronaldo Effect” in Manchester, Juergen Klopp's latest thoughts, Wenger's big idea
Anders mytologiserar en nickning till en jäktad Steven Gerrard på en gata i Liverpool 2011. Johan tänker på Yngwie Malmsteen när Ronaldo, Schmeichel och Wenger berättar hur festligt det vore med VM vartannat år.Dessutom: Fabrizio Romano, Kjell Höglund, ”Magiskt surr” med Ismael Diawara, experter med dobbarna på, mellanbarnet ÖSK och lättstyrda legendarer i flip-flops.
Duncan Castles joins Ian McGarry to 'bring you the news before it becomes news' from the biggest clubs in world football.Your Questions AnsweredArsenal consider Arteta replacementsWenger's World Cup: All about the money?What next for Martial?Was Ronaldo really ready to join Man City?Gavin Williamson mistaken identity award
An All Whites legend is clear where he stands on a potential change capturing the attention of the football world. Global governing body FIFA, via a project led by former Arsenal manager Arsene Wegner, are exploring the possibility of holding the World Cup every two years, instead of every four. The latest step in the process is taking place in Qatar this week, with Wenger joined by FIFA president Gianni Infantino and a group of former star players and coaches to further discuss the proposal. Part of that group is All Whites legend Ryan Nelsen, and the former New Zealand captain told Clay Wilson he's backing the already polarising idea to alter the cycle of the world's biggest sports tournament.
Following a proposal by the Saudi Arabian Football Federation in May, FIFA is now carrying out a feasibility study into the practicalities of altering the World Cup cycle from four years to two. The study is being led by former Arsenal manager Arsene Wenger (now FIFA's Chief of Global Football Development) who was run out of Arsenal by their fans. Is he going to ruin the World Cup next?
Talking Tactics discuss how Naby Keita might be feeling in Guinea, and how Paul Pogba might have changed things, if at all. Were health officials playing a larger game during Brazil v Argentina? UCL draw, and Have Hope updating his list of margins. The passing of Jean-Pierre Adams. Questions on Tammy Abraham, Messi v Ronaldo, Wenger changing the World Cup (forgive the ranting). Also, can you compare footballers to video game consoles? Think about becoming a patron... https://www.patreon.com/join/talkingtactics Rate us five stars on Apple Podcasts! https://www.getpodcast.reviews/id/1127264410 Follow Talking Tactics https://www.twitter.com/taIkingtactics https://www.instagram.com/talkingtactics https://www.facebook.com/talkingtactics352 Talking Tactics Special Coup de tête: https://bit.ly/2DXSMVk Have Hope's Website https://havehopefootballhut.com Follow us https://www.twitter.com/HaveHopeHut https://www.twitter.com/Ankaman616 https://www.twitter.com/DanielTiluk
L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).
Feargal Brennan, Pete Hall and Ant McGinley on duty to review the 2022 World Cup qualifying action this weekend.England picked up back to back 4-0 wins as Gareth Southgate's much changed side cruised to a 4-0 Wembley victory over minnows Andorra.Southgate opted to rotate his options with Liverpool star Trent Alexander-Arnold in midfield alongside Three Lions debutant Patrick Bamford in attack.The gang also look back at some Gareth Bale magic for Wales and another disappointing night for the Republic of Ireland against Azerbaijan.Arsene Wenger has also had his say on the Premier League's spending amid links to Borussia Dortmund hotshot Erling Haaland as well as big money contract updates for Mo Salah and Phil Foden.
C'est le retour du FC Stream Team avec Maxime Dupuis et Martin Mosnier. Et pour entamer cette 6e saison, l'équipe de France est évidemment au programme. L'attaque des Bleus occupe le premier sujet avec cette question : Faut-il sacrifier un des membres du trio d'attaque ? Si oui, lequel : Mbappé, Griezmann ou Benzema.Dans un deuxième temps, ils reviennent sur le parcours de Didier Deschamps à la tête des Bleus depuis quelques mois et expliquent en quelques dates, comment l'autorité du sélectionneur s'est délité.Pour conclure, retour sur la proposition d'Arsène Wenger d'organiser une Coupe du monde tous les deux ans ? Pourquoi cette volonté . Est-ce qguidé seulement par l'argent ? Maxime Dupuis et Martin Mosnier vous détaillent leurs arguments. Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.
Reif mit Star-Gast Arsène Wenger über die Pläne der FIFA für zukünftige Weltmeisterschaften mit 48 Mannschaften und alle zwei Jahre, über die Premiere League mit dem Überraschungs-Transfer von Ronaldo und der Situation als Tabellenletzter vom FC Arsenal sowie dem deutschen Fußball nach dem Länderspiel gegen Liechtenstein.
Bom dia! Hoje, no Futebol de Verdade, vou falar-vos do projeto subscrito por Arsène Wenger, que prevê um Mundial é um Europeu a cada dois anos. Continuarei ainda a refletir acerca do plano de jogo da seleção nacional e falar-vos-eu das surpresas que ontem fizeram tropeçar a Itália e cair a Espanha. Ao ataque! Não se esqueçam de subscrever o canal e de me seguir nas redes: Facebook - https://bit.ly/2KuTzUd Instagram - https://bit.ly/2ORMEII Twitter - https://bit.ly/2Ksyf1
In this blog, Seth will dive deep into the players, the expectations, the manager, and the transfers that Arsenal have made over the past few years, especially after Wenger left and why there's still hope for the future. Visit here for the written version of this blog. See all the Five Blokes blogs at https://thefiveblokes.com/podcast Visit thefiveblokes.com to follow the Five Blokes fantasy league and follow the blokes. Visit www.etsy.com/shop/TheFiveBlokes?ref=search_shop_redirect to buy Five Blokes merch --- Send in a voice message: https://anchor.fm/the-five-blokes/message
This week on Rural Health Leadership Radio we are having a conversation with Dr. Hannah Wenger, a clinical care specialist on the Rosebud Indian Reservation, and faculty member at Massachusetts General Hospital. Hannah is a physician who is passionate about providing culturally relevant care to the residents of the community she serves. “What does allopathic medicine have to do with a traditional ceremony like a sweat lodge? I would argue it has a lot to do with it” ~ Hannah Wenger M.D. Hannah Wenger, MD, is a general internist and faculty member at Massachusetts General Hospital (MGH) having just completed MGH's Fellowship Program in Rural Health Leadership. She obtained her undergraduate degree in biology at the University of Notre Dame and her medical degree at the University of Chicago Pritzker School of Medicine. She then completed an internal medicine residency and a clinical medical ethics fellowship at the University of Chicago. As a rural health fellow at MGH, Dr. Wenger currently provides clinical care to the Sicangu Lakota Oyate on the Rosebud Indian Reservation in South Dakota. Her interests include Two Spirit and LGBTQ health, hepatitis C, and clinical ethics.
Kate, Pete and Jim settle in to wonder whether Jack Grealish will soon slide his glorious calves into some walking boots and trudge up to Manchester City.Elsewhere, Arsène Wenger has been linked to a gloriously suave return to management while his compatriot Raymond Domenech continues to take as much undeserved credit as possible. There's also a return for Virgil van Dijk and the first-ever round of Kate's Game!We're back with daily episodes Monday-Friday, so make sure you're subscribed in your podcast app so you never miss an episode!Search ‘Football Ramble' on social media to find us, and email us here: email@example.com.***Please take the time to rate and review us on Apple Podcasts or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** See acast.com/privacy for privacy and opt-out information.
In our Final Episode of The Arsenal History season we look at the Wenger Era. The success of 3 league titles 7 FA Cups and The Invincible Season which ultimately lead to a 49 game undefeated . We then reflect on the departure of a manager that was groundbreaking for the club and try to understand how history might remember him. Enjoy , Share & Subscribe
Ofsajdová situace, kterou sudí posoudí často jinak, než vidíte vy sami doma na zvětšeném záběru prošpikovaném červenými a modrými čarami. Těmto blamážím chce Premier League říct Dost! Ale zvolila dost svéráznou metodu.Anglická nejvyšší fotbalová soutěž zvětšuje v novém ročníku tloušťku čáry, podle které se u monitorů posuzují ofsajdy. O smyslu takového kroku se ve zbrusu nové rubrice podcastu Angličan „Pro a proti“ konstruktivně pohádali sportovní komentátor Jaromír Bosák a fotbalový expert Seznam Zpráv Luděk Mádl.Autor podcastu Angličan Jiří Hošek v úvodu vzorně shrnul nejnovější úpravu pravidel pro posuzování ofsajdového postavení. Právě sporné situace kolem ofsajdů kazily snad vůbec nejčastěji divákům zážitek ze hry, a to ještě v kombinaci s výrazně nadužívaným VARem, ze kterého se místo vítaného pomocníka stal spíš krutý pán.V loňském ročníku Premier League se nekompromisním digitálním pravítkem přezkoumávala každá gólová akce, letos má snad dojít k evoluci.„Oficiálně se narýsovaná čára určující ofsajd, kterou vídáme i my na televizních obrazovkách, o něco rozšíří. Zatím ovšem není jasné o kolik. Angličtí sudí se pokusí s o něco tlustší čarou zamezit vzniku sporných situací z loňské sezony, kdy při přezkoumání VARem rozhodovaly doslova milimetry, nehty na palci“ uvádí debatu Hošek.Nově se navíc bude postavení mimo hru měřit od kloubní jamky v podpaží, což si samotní hosté Angličana během odchodu ze studia dokonce fyzicky vyzkoušeli.Podle Jaromíra Bosáka, jemuž byla přidělena role zastánce novinky, je aktualizovaná úprava krokem vpřed pro atraktivnější fotbal. „Ačkoliv pro mě byla říše čar a geometrie vždy cizí, pokud budou čáry širší, zákonitě ubude ofsajdů. Když budou mít útočníci více prostoru, uvidíme i více branek. Jakožto příznivec ofenzivního fotbalu jsem jednoznačně pro tenhle krok,“ obhajuje změnu přesvědčivým tónem Bosák.Tomu ale věcně oponuje Luděk Mádl, jenž vidí v novém řešení staré potíže. „Každá čára je v téhle otázce podle mého vlastně nesmysl. Mně se například líbilo řešení, s nímž přišel Arsène Wenger, bývalý dlouholetý manažer Arsenalu. Ten navrhoval, ať se měří ofsajd až tehdy, kdy se těla obránce s útočníkem vůbec nekryjí,“ otřepal revoluční myšlenku francouzského stratéga Mádl.„Jenže takové pravidlo by pravděpodobně odsoudilo obránce k větší pasivitě a fotbal by se stal nekoukatelným. Ve strachu z ofsajdu by klesali bránící hluboko na vlastní polovinu. Navíc když si představím, že by například čahouna z nizozemské reprezentace Weghorsta bránil Plavšič, měl by vytáhlý útočník výhodu metru navíc a přesto by stál ve zcela povoleném postavení,“ přemítá nahlas Bosák.Kdo koho v emotivní debatě přesvědčil, tedy pokud vůbec, se dozvíte v nejnovějším podcastu Angličan. Řeč v něm dojde i na téma povinného očkování anglických fotbalistů i fanoušků, platových stropů v anglickém fotbale a nejnovějších přestupů v rámci Premier League. Poslechněte si celou epizodu!------ Angličan je fotbalový podcast Jiřího Hoška (@hosekj) a jeho přátel věnovaný čistě Premier League. Vychází každé úterý v poledne. Další podcasty, ale taky články, komentáře a videa najdete na zpravodajském serveru Seznam Zprávy. Poslouchejte nás na webu nebo ve vaší oblíbené podcastové aplikaci. Vaše názory, návrhy, otázky, stížnosti nebo pochvaly můžete posílat na firstname.lastname@example.org nebo na @PodcastAnglican. Sledujte @SeznamZpravy na sociálních sítích: Twitter // Facebook // Instagram. Seznam Zprávy jsou zdrojem původních informací, nezávislé investigace, originální publicistiky.
Dan Mosher, Dave Ressler and Clay Wenger -the "Coaches of the Year" for all 3 high school divisions! Join us to reveal the trials and tribulations of coaching and succeeding in the year of the virus (COVID-19). These 3 individuals are remarkable and well worth getting to know. Thanks to this episode's sponsors and partners! Montrose Auto Group: www.gomontrose.com ServPro: www.servpro.com Defense Soap: www.defensesoap.com Next Level Continuing Education: Cimoroni Couture: (216)-287-1522 Montrose Auto Group: www.montroseautooutlet.com Check out more of Coach Cimoroni and "Blood Time" at: www.maverickpodcasting.com Did you know, the "Blood Time Podcast" is now available on the Evergreen Podcast platform as well? Check it out: www.evergreenpodcast.com --- Support this podcast: https://anchor.fm/bloodtime/support
CardioNerds Cardio-OB series co-chairs University of Texas Southwestern Cardiology Fellow, Dr. Sonia Shah (FIT, University of Texas Southwestern) and Dr. Natalie Stokes, (FIT, University of Pittsburgh) join Dr. Nanette Wenger, Professor of Medicine in the Division of Cardiology at the Emory University School of Medicine and a consultant to the Emory Heart and Vascular Center and Dr. Sharonne Hayes, Professor of Internal Medicine and Cardiovascular Diseases and founder of the Women's Heart Clinic at Mayo Clinic for an in depth discussion about lifelong advocacy for women's cardiovascular health. Audio editing by CardioNerds Academy Intern, Dr. Leticia Helms. CardioNerds Cardio-Obstetrics Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Guest Profiles - Advocacy for Women's Cardiovascular Health Dr. Nanette Wenger Dr. Nanette Wenger is Professor of Medicine in the Division of Cardiology at the Emory University School of Medicine. Dr. Wenger received her medical degree from Harvard Medical School in 1954 as one of their first female graduates followed by training at Mount Sinai Hospital where she was the first female to be chief resident in the cardiology department. She is among the first physicians to focus on heart disease in women with an expertise in cardiac rehabilitation and geriatric medicine.Dr. Wenger has received numerous awards including the Distinguished Achievement Award from the Scientific Councils of the American Heart Association and its Women in Cardiology Mentoring Award, the James D. Bruce Memorial Award of the American College of Physicians for distinguished contributions in preventive medicine, the Gold Heart Award, the highest award of the American Heart Association, a Lifetime Achievement Award in 2009 and the Inaugural Bernadine Healy Leadership in Women's CV Disease Distinguished Award, American College of Cardiology. She chaired the U.S. National Heart, Lung, and Blood Institute Conference on Cardiovascular Health and Disease in Women, is a Past President of the Society of Geriatric Cardiology and is past Chair, Board of Directors of the Society for Women's Health Research. Dr. Wenger serves on the editorial boards of numerous professional journals and is a sought-after lecturer for issues related to heart disease in women, heart disease in the elderly, cardiac rehabilitation, coronary prevention, and contemporary cardiac care. She is listed in Best Doctors in America. Dr. Sharonne N. Hayes Sharonne N. Hayes, M.D., studies cardiovascular disease and prevention, with a focus on sex and gender differences and conditions that uniquely or predominantly affect women. With a clinical base in the Women's Heart Clinic, Dr. Hayes and her research team utilize novel recruitment methods, social media and online communities, DNA profiling, and sex-specific evaluations to better understand several cardiovascular conditions. A major area of focus is spontaneous coronary artery dissection (SCAD), an uncommon and under-recognized cause of acute coronary syndrome (heart attack) that occurs predominantly in young women. Dr. Hayes also studies the diagnosis and treatment of nonobstructive (microvascular) coronary artery disease and chest pain syndromes and the subsequent risk of arrhythmias and other cardiac conditions in women who have had hypertension, diabetes or preeclampsia during a pregnancy. With the Pericardial Disease Study Group, Dr. Hayes is assessing the optimal management of pericarditis. Additionally, Dr. Hayes is involved in several research initiatives aimed at addressing health equity and reducing health disparities. Through partnerships with national professional women- and minority-serving organizations, Dr. Hayes assesses barriers faced by women and minorities that prevent or deter them from participa...
Are you desperate for financial breakthrough? Are you tired of living in the stress of financial worry? Are you done feeling crushed by the weight of financial struggles? As Leah continues our series, "Fresh" she shares what God's best plan for our finances looks like.
Camarena Tequila Presents: The Men in Blazers Arsène Wenger Pod Special. The exclusive, extended conversation between Rog and legendary Arsenal manager Arsène Wenger. The man who revolutionized English football discusses his path from fringe player at Racing Strasbourg to the largest stages in global football. Camarena Tequila is 40% alcohol by volume, please enjoy responsibly.
On July 11, 2021, theologian Sara Wenger Shenk preaches at a Park View Mennonite Church Sunday morning service from Ephesians 4:1-6; 14-16 and based on her book "Tongue-Tied: Learning the Lost Art of Talking About Faith".
Sexual addiction comes with baggage and stigma. It's hard to navigate without help. Matt Wenger, clinical therapist and expert in sex addiction shares how getting help is a step by step process. Find more from Matt at BeginAgainInstitute.com Get closer to yourself and your spirit wit Dr. April's latest ebook, Improving Intimacy: It Starts with YOU! on Amazon at https://amzn.to/3hAmYvl Learn more about your ad choices. Visit megaphone.fm/adchoices
If you are curious about what really happens at a residential trauma intensive, take a listen to my conversation with Matt Wenger, Clinical Director of Boulder Recovery as he takes us behind the scenes at his 14-Day Intensive for men struggling with sex, porn, and relationship issues. The program uses the TINSA® treatment model (Trauma Induced Sexual Addiction) to heal the traumatic experiences and attachment wounds driving addictive behaviors and problematic thinking around sex and intimacy. Boulder Recovery is also the only Christian intensive in North America that includes support for partners impacted by the trauma of betrayal through online psychoeducation, care and interaction during the men's intensive with a betrayal trauma specialist. In this episode you will learn: How an intensive experience differs from weekly individual therapy What different healing modalities are used to treat trauma What actually happens during the different stages of the intensive What support for partners is available What is the best time to attend an intensive Fight For Love Website Fight For Love Book Fight For Love Private Online Support Group
Timmy was lucky to get to have a real life scientist in studio for a conversation on so many things relating to the life, love, religion, faith, science, biology, aliens, and so much more. --- Support this podcast: https://anchor.fm/timmygibson/support
In this week's episode, we continue our examination of different learning theories and theorists and dig into Situated Learning: Legitimate Peripheral Participation by Lave and Wenger. The book examines how different cultures and professions enculturate newcomers into their communities of practice. Things that bring us joy this week: Japanese Breakfast - Be Sweet (http://japanesebreakfast.rocks/) Mare of Easttown (https://www.hbo.com/mare-of-easttown) Check out Saturday Night Live's Durder Murder skit (https://youtu.be/qaKZi6p6sxg) Intro/Outro Music: Notice of Eviction by Legally Blind (https://freemusicarchive.org/music/Legally_Blind)
Guest: Nanette K. Wenger, MD, MACC, MACP, FAHA What do we need to know about cardiovascular complications during pregnancy? Dr. Nanette Wenger, a Professor of Medicine in the division of cardiology at the Emory University School of Medicine, reviews what cardiologists know about pregnancy complications and the risk of coronary artery disease.
In Hawaii, Will McGough is a consummate professional tour guide. On today's show, he's putting his tour guests on blast for their obnoxious behavior. That includes showing up late, puking on the bus, and going to KFC during the trip. And yes, he has indeed left people behind for being 10 minutes late. There's also a lively discussion about how the “unwritten rules of travel” are bullsh*t, and a contentious argument between Will and Eben about whether a “SPAM McDouble” qualifies as a cultural experience.In Hot Takes, Tim “seasoned flyer” Wenger reveals his greatest (and completely rational) fear on airplanes, and Eben officially launches FEA (Fast Eaters Anonymous). Wake and WanderEben's InstagramTim's Instagram
Join Claire, Rachael and their very special guest, Chris Wenger as they discuss the importance of addressing social learning, self-advocacy and generalizing pragmatic skills with adolescents. You can find Chris on Instagram at @speechdude, Tik Tok at @speechdude and visit his website at speechdude.com. Please remember to review, rate and subscribe! Thank you! If you have any questions, concerns or would like to suggest a future topic, email us over at email@example.com. You can also find us on Instagram @letstacoboutspeechpodcast and visit our website at letstacoboutspeech.com! --- Support this podcast: https://anchor.fm/lets-taco-bout-speech/support
As I listened to Sara, I was reminded of what a privilege it is for me but for all of us to hear the stories from the saints who have honed their life with God as "explorers" (Sara's word) in the vast and mysterious landscape of the Spirit. Sara ties our reticence to share our faith to a number of qualities that include our failure to notice, to be still, to pay attention to the mysterious nature of God and yet a mysteriousness that is manifested all around us and within us. Sara is one who in her words has always been restless within the church, who has been dissatisfied with the "Christianese" of the church language that seems so disconnected from reality. She confesses, for example, that she has struggled to be able to name her "call" in the way that so many assume a good Christian should be able to do. Instead of call as "doing," Sara sees her call as one of "being" by virtue of living with integrity. "I have always been pushing against the walls of the church," she notes, and along with her husband Gerald, has expressed this over time by creating new and experimental faith communities. Sara notes the importance of paying attention to our bodies as we practice our life with God. Once again friends, this is was a sacred moment of listening to the life of one who knows God.
This week, Jamie's guest is an Arsenal legend… who else but Ian Wright, Wright, Wright! Ian talks about his journey from Sunday league football to the Premier League, the impact of Dennis Bergkamp & Arsène Wenger, his England disappointments, the famous goal celebration vs Tottenham and his punditry development. Ian also tells Jamie his greatest game and ultimate 5-a-side team. Follow us on:Instagram: @greatestgamepod Twitter: @greatestgamepod Email: firstname.lastname@example.org
It's the final 'Stadio' before the Euros, so Musa and Ryan look back on PSG and Bayern winning the women's domestic leagues in France and Germany (06:29), Colón winning their first title (12:36), and the USMNT winning the inaugural CONCACAF Nations League, beating Mexico, and what this means for the U.S. (13:56) Then, it's a Champions League what-if special, where they discuss what would have happened if Borussia Dortmund had won in 2013 (31:58), if Atlético Madrid had won in 2014 (44:47), and if Arsène Wenger, rather than Hansi Flick, had replaced Niko Kovac at Bayern (51:58). Hosts: Musa Okwonga and Ryan Hunn Additional Production Assistance: Isaiah Blakely Learn more about your ad choices. Visit podcastchoices.com/adchoices
'Fever Pitch' is widely regarded to be the best football book ever written. It's been made into two films, won the 1992 William Hill Sports Book of the Year award and inspired countless football fans around the UK to think more deeply about their football fandom. Its author, Nick Hornby, joins us in the studio for today's episode of the Book Club!Nick sits down with Kate and Jim to remember the seismic impact of 'Fever Pitch', nearly thirty years after its initial publication. Nick's footballing obsession embedding itself within every aspect of his life and the book encapsulates the joy, frustration, hopelessness and deliriousness felt by a generation of football fans on the terraces every Saturday. From his deep love for Arsène Wenger to the state of the modern game, it's a fascinating chat with one of the forefathers of modern football writing!You can purchase the latest edition of 'Fever Pitch' here.***Please take the time to rate and review us on Apple Podcasts or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** See acast.com/privacy for privacy and opt-out information.
Welcome back to the Mastermind Effect! I Am Juli Wenger, here to hijack the solo show to talk about Comparison and Impostor Syndrome. Check it out! [00:01 – 01:11] Opening Segment An insight into this hijacked episode Interested in a Chat with me? DM me on Instagram! [01:12 – 08:43] Comparison and Impostor Syndrome Comparison and Impostor syndrome How they tie into our inner critic A quick personal story Getting clear on our purpose and allow that to be our guide Having other people around you that support and genuinely cares for you Breaking free from the impostor syndrome A quick reflection Connect with me! Send me a DM on Instagram Final Thoughts Tweetable Quotes: “Comparison breeds impostor syndrome.” - Juli Wenger “Get clear on what you want, and allow that to be the guide.” - Juli Wenger “You must have other people who love you, care about you, support you, do not shame you, and will not allow you to sit in shame. Who will remind you of who you are, and to get you out of impostor syndrome.” - Juli Wenger Resources Mentioned: https://www.juliwenger.com/ (Juli Wenger) https://thebecomingourselvespodcast.buzzsprout.com/ (The Becoming Ourselves Podcast) https://www.juliwenger.com/becomingourselvesthesummit (The Becoming Ourselves Summit) Connect with Juli on https://www.instagram.com/juliwenger/ (Instagram) or visit https://www.juliwenger.com/ (https://www.juliwenger.com/) It's time to Stand Up, Show Up, and Level Up! Download The Success Finder on Apple and Google Play Store. You can connect with me, Brandon Straza, onhttps://www.linkedin.com/in/brandonstraza/ ( LinkedIn),https://www.instagram.com/brandonstraza/ ( Instagram), or send me an email athttps://email@example.com ( firstname.lastname@example.org). I'd love to get in touch and talk more about personal development and how you can live past beyond your limits.
Juli Wenger serves as an Enneagram Expert, Empowerment Coach, Motivational Speaker and Facilitator, and Growth Junkie passionate about all things self-awareness, self-compassion, courage, and resilience. Her journey includes everything from training as a Human Ecologist and Interior Designer, to a 10-year career running a multiple 6-figure real estate business, to jumping out of said business after realizing there was more to life for her. Once filled with imposter syndrome, fear, excitement, and also a deep knowing that the impact available to be created was too important to let her fear stop her. In this episode, Juli gets into how Our learning is formed by the interactions with the people around us. She explains how Masterminds are a way that YOU are able to be called UP! Juli gets into what she does with her clients by asking: who are you, what drives you, and what's the next expansion. Check it out! [00:01 – 02:12] Opening Segment I introduce our guest, Juli Wenger I briefly talk about the great values that await you in this episode Connect with our guest. See links below. [02:13 – 18:20] Juli's learning journey and Masterminds How Juli's learning changed from her early years vs today From reading and absorbing to listening and watching others Understanding how people functioned Juli's Coaches and Masterminds Quick breathing exercises How Masterminds have helped Juli resetting and getting unstuck The power of finding the right mastermind [18:21 – 26:29] Self-Education and Juli's reality The parallels of self-education and standard education moving forward The support provided by standard education to our self-education What to expect when working with Juli Building on your foundation and goals Figuring out what's stopping you from accomplishing your goals Success Stories from Juli's Mastermind Owning your success and leaning into your passion to make an impact [26:30 – 33:14] Creating Success A key ingredient/attribute to being successful Getting clear on your purpose Exciting things in store for Juli in the next few months Actionable Items/Tips from Juli Take time daily to do a breathwork exercise to help you focus Final Thoughts Tweetable Quotes: “Learning is so much more informed by understanding how people are wired. Understanding based on our interactions, and just really leaning into seeing how people see through different lenses.” - Juli Wenger “Busy doesn't equal abundance. Busyness can actually block abundance.” - Juli Wenger “It's so important that we own our own successes.” - Juli Wenger “Anything we want to achieve, any expansion or growth that we want to go through comes back to us, and our own work on us.” - Juli Wenger “People need to understand that, regardless of what they work on, everything boils down to them getting in their own way.” - Juli Wenger Resources Mentioned: https://www.juliwenger.com/ (Juli Wenger) https://thebecomingourselvespodcast.buzzsprout.com/ (The Becoming Ourselves Podcast) https://www.juliwenger.com/becomingourselvesthesummit (The Becoming Ourselves Summit) Connect with Juli on https://www.instagram.com/juliwenger/ (Instagram) or visit https://www.juliwenger.com/ (https://www.juliwenger.com/) It's time to Stand Up, Show Up, and Level Up! Download The Success Finder on Apple and Google Play Store. You can connect with me, Brandon Straza, onhttps://www.linkedin.com/in/brandonstraza/ ( LinkedIn),https://www.instagram.com/brandonstraza/ ( Instagram), or send me an email athttps://email@example.com ( firstname.lastname@example.org). I'd love to get in touch and talk more about personal development and how you can live past beyond your limits.
This week is a Double Feature Circulation on the Run. Please join authors Alexander Benz and Lars Wallentin as they discuss their article "Biomarker-Based Risk Prediction With The ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation." Then, please join author Timothy McKinsey, editorialist Thomas Gillette and Associate Editor Sergio Lavandero as they discuss the article "HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling" and the editorial "HDAC Inhibition in the Heart: Erasing Hidden Fibrosis." TRANSCRIPT BELOW Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts, I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Greg, I cannot get enough of our double features, and this one's really nice because it's a clinical feature and a preclinical feature, and both are just phenomenally interesting. The first is about the ABC-AF scores. In case you don't recognize it, well, then you just have to listen. Very, very important information on biomarker-based risk prediction in patients with atrial fibrillation, not receiving oral anticoagulation. Then we've got a really interesting paper talking about HDAC inhibition and diastolic dysfunction. Interested? Well, listen up. Dr. Carolyn Lam: First, let's talk about some of the papers in today's issue, shall we? I want to start, Greg. You grab your coffee. I need to talk about this first one, which really provides the first extensive genetic and phenotypic landscape of a very important condition, peripartum cardiomyopathy. This is from Dr. Arany and colleagues from Perlman School of Medicine, University of Pennsylvania. What they did is studied 469 women with peripartum cardiomyopathy, who were identified from several US and international academic centers. They acquired clinical information and DNA samples. Next-generation sequencing was performed on 67 genes and evaluated for the burden of truncating and missense variance. Dr. Carolyn Lam: What they found was that women with peripartum cardiomyopathy bear a significantly high burden of loss of function variants in a number of genes, including familiar ones like TTN, FLNC, DSP, and BAG3. The identity and relative abundance of these variants were remarkably similar to that seen in idiopathic dilated cardiomyopathy, indicating that the genetic predisposition to peripartum cardiomyopathy and dilated cardiomyopathy may be one in the same. Now, while peripartum cardiomyopathy patients with the TTN truncating variants presented with lower ejection fraction. No significant differences in the rates of recovery were seen. Dr. Greg Hundley: Really interesting, Carolyn. Clinically, what are the implications today as we see these patients? Dr. Carolyn Lam: Well, I think the most important one is that genetic counseling and testing should, perhaps, be considered for women with peripartum cardiomyopathy, following the guidelines for dilated cardiomyopathy. What about you, Greg? Dr. Greg Hundley: Very nice, Carolyn. Well, my paper evaluates the role of inflammation and outcomes in patients that sustain out-of-hospital cardiac arrest. It comes to us from Dr. Martin Meyer from Rigshospitalet. Carolyn, out-of-hospital cardiac arrest patients who remain comatose after initial resuscitation are at high risk of morbidity and mortality due to the ensuing post-cardiac arrest syndrome. Now, systemic inflammation constitutes a major component of the post-cardiac arrest syndrome and interleukin 6 levels are associated with this severity. The IL-6 receptor antagonists tocilizumab could potentially dampen inflammation after post-cardiac arrest. The objective of the present trial was to determine the efficacy of tocilizumab to reduce systemic inflammation after out-of-hospital cardiac arrest, A presumed cardiac cause, and thereby potentially mitigate organ injury. Dr. Carolyn Lam: Oh, wow. Interesting, Greg. what did they find? Dr. Greg Hundley: Carolyn, they had 80 comatose out-of-hospital cardiac arrest patients and they were randomized 1:1 in a double-blind, placebo-controlled trial to a single infusion of tocilizumab or placebo, in addition to standard of care, including targeted temperature management. The primary endpoint of the study was reduction of CRP response. This was achieved by tocilizumab, as there was a significant treatment-by-time interaction. Systemic inflammation was reduced by treatment with tocilizumab, as both CRP and leukocyte levels were markedly reduced. Now, myocardial injury was also reduced, documented by reductions in CK-MB and troponin T. However, there were no differences, Carolyn, in survival or neurological outcome. So Carolyn, it looks like for those that survive an out-of-hospital cardiac arrest and do experience neurological recovery, there could be cardiac benefits. Dr. Carolyn Lam: Wow, very interesting. I cannot imagine how difficult it must've been to perform such a trial. Thanks, Greg. Well, the next paper demonstrates a new mechanism underlying diastolic dysfunction, and provides theoretical and experimental evidence to explain, perhaps, the ineffectiveness of conventional nitric oxide enhancement trials for HFpEF. And you know, that's my favorite topic. Dr. Greg Hundley: Wow, Carolyn, really interesting. Can you summarize it for us? Dr. Carolyn Lam: Sure. Well, first of all, this comes from Doctors Eom and Kook from Chonnam National University Biomedical Research Center in Korea. These authors used two animal models of diastolic dysfunction, the salty drinking water, unilateral nephrectomy with aldosterone, or SAUNA, model, and a mild transverse aortic constriction model. They also looked at human heart samples from patients with left ventricular hypertrophy. Dr. Carolyn Lam: Together, in very, very elegant experiments, they showed that neuronal nitric oxide synthase was upregulated in diastolic dysfunction, which increases S-nitrosylation and cardiomyocytes, and its pharmacologic inhibition, as well as genetic ablation, alleviated diastolic dysfunction. Now, specifically, protein S-nitrosylation of histone deacetylase 2, or HDAC2, played a critical role in the development of diastolic dysfunction and nitric oxide reduction and the following protein denitrosylation may provide a novel therapeutic strategy for HFpEF. Dr. Greg Hundley: Very nice, Carolyn. Well, my next paper comes from Dr. William Pu from Boston Children's Hospital and looks at reactive oxygen species-mediated CaM kinase 2 activation, and how that contributes to calcium handling abnormalities and impaired contraction in the Barth syndrome. Carolyn, mutations in tafazzin, a gene required for biogenesis of cardiolipin, the signature phospholipid of the inner mitochondrial membrane, causes Barth syndrome. Carolyn, remember that Barth syndrome occurs primarily in males, is associated with cardiomyopathy, a low white count, and recurrent infections, and also skeletal muscle myopathy and short stature. Cardiomyopathy and the risk of sudden cardiac death are prominent features of the Barth syndrome, but the mechanisms by which impaired cardiolipin biogenesis causes cardiac muscle weakness and these arrhythmias are poorly understood. Dr. Carolyn Lam: Oh, Greg, thanks so much for not quizzing me on that one. I was trying to remember what Barth syndrome is, and thanks for the review. Okay, so what did they find? Dr. Greg Hundley: Right, Carolyn. The investigators identified a molecular pathway that links tafazzin mutation to abnormal calcium handling and decreased cardiomyocyte contractility. This pathway may offer therapeutic opportunities to treat Barth syndrome, and potentially other diseases with elevated mitochondrial reactive oxygen species production. Dr. Carolyn Lam: Thanks, Greg. Nicely summarized. Well, let's go through what else there is in today's issue. There is a Perspective piece by Dr. Singh, entitled The Morbidly Obese Patients with Symptomatic Atrial Fibrillation: Why are we Holding Back on Bariatric Surgery? There's an On My Mind piece by Dr. Wenger on the incremental change versus disruptive transformation: COVID-19 and the cardiovascular community. There's also a research letter by Dr. Phillip on cardiovascular evaluation after COVID-19 in 137 collegiate athletes, and it's the results of an algorithm-guided screening. A very interesting piece. Dr. Greg Hundley: Very nice, Carolyn. Well, Carolyn, in the mailbag, I've got an exchange of letters regarding the article Anti-Inflammatory Actions of Soluble Ninjurin-1 and the Amelioration of Atherosclerosis with Dr. Zheng, Jianmin, and Oh. Then finally, Dr. Rob Califf has an On My Mind piece, entitled Avoiding the Coming Tsunami of Common Chronic Disease: What the Lessons of the COVID-19 Pandemic Can Teach Us. Well, Carolyn, I'm really excited. Another double feature Tuesday. How about we turn our attention and move toward those articles? Dr. Carolyn Lam: Yep. Something for everyone in this one. Let's go. Today's feature discussion will sound somewhat familiar if we're talking about the ABC scores. Now, remember that stands for age, biomarkers, clinical history scores, and they're the scores that we use in patients with atrial fibrillation receiving oral anticoagulation, or at least that's the data we have so far. But, what are the utilities of these ABC scores in patients not receiving oral anticoagulation? Dr. Carolyn Lam: Well, guess what? That's what today's feature paper is all about. I'm so pleased to have with us today, the first author, Dr. Alexander Benz, from Population Health Research Institute, McMaster University in Canada, as well as Dr. Lars Wallentin, he's a senior author from Uppsala University in Sweden. Welcome, gentlemen. Alex, if I could start with you, please. A very interesting question and not so easy to answer, could you please tell us a little bit about the background to your study, what you did, and what you found? Dr. Alexander Benz: Sure. Thanks for the opportunity to speak here. The ABC scores have now been shown to outperform clinical risk scores in the setting of patients with AFib receiving oral anticoagulant therapy. But so far, nobody has ever looked at the performance of these scores in patients who are not treated with oral anticoagulant therapy. So here we validated the ABC stroke, bleeding, and death scores in patients with AFib who were not receiving oral anticoagulant therapy. We chose the ACTIVE A and AVERROES trials, where patients were randomized to receive antiplatelet therapy, so aspirin or aspirin plus clopidogrel, for the validation study. We ended up studying the scores and over 4,300 patients who were receiving either aspirin, which were over 3,195 patients, or aspirin plus clopidogrel in about 1100 patients, in these studies. Dr. Alexander Benz: Now, we found that the ABC stroke score was superior to the CHA2DS2–VASc score, yielding a C-index of 0.7. The ABC bleeding score was also better than the currently recommended HAS-BLED score for the assessment of the risk of bleeding, yielding an overall C-index of 0.73. And finally, the ABC-AF death score yielded a C-index of 0.78, which I think is remarkable. Dr. Alexander Benz: Now, as these scores were derived from patients receiving oral anticoagulant therapy, we're not surprised to see that the ABC stroke score underestimated the risk of stroke in this population. And very similarly, the ABC bleeding score overestimated the risk of bleeding in these patients receiving antiplatelet therapy. So these scores, the ABC stroke and bleeding scores, were recalibrated for our prediction of absolute event rates in the absence of oral anticoagulant therapy. Dr. Carolyn Lam: Thanks, Alex. That was a beautiful summary. Now, Lars, if I could ask you, please, could you really highlight to all of us, what is the key thing about validating these scores in patients with atrial fibrillation, but not receiving oral anticoagulation? Dr. Lars Wallentin: I think what people like to have is an estimate of the risk of stroke and the risk of bleeding. If you start them on oral anticoagulation and that has been difficult, we only knew this based on the risk scores on patients that were on treatment. But if we now are using this score, which are also well-calibrated, we can really estimate the absolute risk of a stroke. Let's say, 3% without oral anticoagulation, then how much is it lowered by oral anticoagulation down to 1%? And we can do this on an individual level, because there is a variability between patients and we can identify the risk for an individual patient without treatment, and the risk on treatment, and that can be balanced then against the risk for bleeding on treatment and without the treatment. And thereby, you can get the precise estimate on the risk-benefit ratio for the individual patients. Dr. Lars Wallentin: This is a precision medicine approach, which we think will provide a better treatment with better outcomes for the patients than we have had before. Also, death can be, of course, involved at the final net benefit, with and without treatment. Therefore, we think this is a great step forward, and this cannot be implemented in the real life because we have used biomarkers that now can be available in the routine laboratories. These are NTproBNP and troponin, which are available in all hospitals, and a new marker, GDF-15, a marker that's related to the bleeding risk and that is currently launched by Roche Diagnostics as a new tool. So I think this is a realistic future to improve treatments. Dr. Carolyn Lam: Dr. Lars, I have to tell you, all us editors fully agreed as well, that this is a great contribution, filling an important gap in the literature so far in a very clinically important question when we face the patient who hasn't started anticoagulation. So really, again, thank you both for this study and for publishing with us. A couple of questions, though. It does require these extra biomarkers that come with some, what can I say, cost of needing to measure them if they're not already measured. Could you give us some idea of how much the scores add to what we're used to, the CHA2DS2–VASc and the HAS-BLED score? I don't know, maybe Alex? Dr. Alexander Benz: Sure. I think one downside of the widely-accepted and also often useD clinical scores is that they rely on Arbitrary categorization and dichotomization of clinical variables, and with biomarkers, we have the great advantage of having a continuous tool to assess the risk of outcomes here. And as Lars mentioned, these are mainly the cardiac biomarkers NTproBNP and cardiac troponin, as well as the GDF-15, or growth differentiation factor 15. We think that biomarkers reflect a powerful tool to also reflect underlying subclinical disease, which is very important, I think, in this stratification, and this is probably where much of the superiority of the biomarker-based tool stems from. Dr. Carolyn Lam: Right, thanks. Back to what Lars had said about more precision, which is exactly what the whole of cardiology is, I think, moving towards as well, but it was very, very clever to look for the studies ACTIVE and AVERROES. Hard to think of the population in which you tested this. But weren't the blood samples in these studies very old? Did you then have to remeasure those biomarkers? Were they reliable? Dr. Lars Wallentin: Yes. These were old samples that were taken at entry into the ACTIVE and AVERROES trial. The investigators in Canada were really very clever to save the sample, but the samples have been saved for a decade or more since then. But fortunately, these assays are very stable over time, so all of them, and therefore the results are reliable. The levels are very similar to the ones we get in the real-life setting for samples as the one we have in ARISTOTLE and RE-LY, where the scores were derived. So this seems to be, I think, also an advantage that this can be used for stored samples, and fresh samples. Dr. Carolyn Lam: Thank you for addressing that so nicely. We're running out of time sadly, but I would love to hear, maybe as final remarks, what you think are the overall clinical implications and perhaps the next steps for important studies that need to be done. Maybe I could ask Alex to start first and then Lars can finish? Dr. Alexander Benz: Well, I think the next steps in the ABC score program will depend on potential integration or a combination of scores, which then may guide physicians in whom to treat or even whom not to treat. Withholding anti-platelet therapy in certain very low-risk patients, that's what comes to mind. I know that Lars and his colleagues are performing a randomized controlled trial in Sweden where they're testing the ABC scores in clinical practice against the usual care with the clinical scores. Maybe, Lars, you want to elaborate on this. Dr. Lars Wallentin: Yeah, I think the final step is, of course, a prospective randomized trial showing which are the real benefits. We are randomizing 6,000 patients to conventional care versus precision medicine-based care using the ABC risk scores. Outcomes are death and stroke and bleeding. I hope that we will find usefulness of this also in a prospective trial, which will be the final piece of evidence, of course. Dr. Carolyn Lam: Wow, Lars, that is amazing. Thank you so much for sharing that with us. First time on Circulation on the Run. Well, audience, I'm sure you enjoyed that. Thank you so much, Lars and Alex. Now, hold on tight, we're going on to our next feature discussion. Dr. Carolyn Lam: Oh, I can't wait to get onto this feature discussion. You see, it's actually going to reveal a potential new way to target diastolic dysfunction. My absolute favorite topic. It's a basic science paper. It is incredible. You're going to hear all about its clinical translational potential and significance, and from none other than the corresponding author, Dr. Timothy McKinsey from University of Colorado School of Medicine, and editorialist of a beautiful accompanying editorial, Dr. Thomas Gillette from UT Southwestern, and Dr. Sergio Lavandero, our Associate Editor from University of Chile, San Diego. Thank you so much for being here. Tim, could I get you started off? Recognizing there are a lot of clinicians listening out there, this is an incredible paper. HDAC, I think for some, it will be the first time you've been hearing such a word. Please, please, could you break it down for us what you did and what you found? Dr. Timothy McKinsey: Sure. Thanks, Carolyn, and thanks for inviting me to do this. It's really a pleasure. HDAC, that stands for a class of enzymes called histone deacetylases, and those are also known as erasers of acetyl marks on chromatin. So they're really famous for the regulation of epigenetics or gene expression. But we found that HDACs do a lot of other things in the heart too, by deacetylating both histone and non-histone proteins, and we're just really interested in the therapeutic potential of inhibiting HDAC enzymes for the treatment of heart failure. And, in so doing, we assess their ability to reverse existing diastolic dysfunction in a mouse model of kidney disease and hypertension. Dr. Carolyn Lam: You know what, Tim, I really liked the way you very carefully said that. A mouse model of diastolic dysfunction with preserved ejection fraction, that I think, previously, a lot of people with just very loosely used the word HFpEF for such a model, but I really, really appreciate how carefully you worded that. Could you tell us a little bit about the model and what you found? Dr. Timothy McKinsey: Sure. Yeah, we've been really careful not to call it a model of HFpEF, because it isn't a model of heart failure. It really is a model of isolated diastolic dysfunction and preserved ejection fraction. It's a model that's been used in the literature in the past, where you perform a uninephrectomy in mice, so remove one kidney, and then implant something called DOCA, which is an aldosterone memetic. And over time, these animals develop systemic hypertension that results in cardiac hypertrophy and diastolic dysfunction. Dr. Timothy McKinsey: We were perplexed because we couldn't see any fibrosis in the model. But when we did a deep dive into fibrosis using more sensitive methods than are traditionally used, we did uncover what we're calling hidden fibrosis. We believe that HDAC inhibitors, our data suggests that HDAC inhibitors, can actually block the formation of hidden fibrosis that leads to diastolic dysfunction. Dr. Carolyn Lam: Very nice. If you could just give us a one-line on how will you find this hidden fibrosis? Dr. Timothy McKinsey: We got stuck on that for years, because we did all the traditional assays to measure cardiac fibrosis, mainly picrosirius red stain, and we didn't see anything. But we were fortunate to team up with some really talented collaborators, including Maggie Lam here at the University of Colorado, who is an expert at using mass spectrometry to study cardiac remodeling, and also Luisa Mestroni and Brisa Peña who use atomic force microscopy to look at tissue stiffness. When we teamed up with those investigators, first with Maggie we found that, sure enough, when we used her sensitive mass spec assay to look at extracellular matrix protein expression in the heart, there was really a profound increase in ECM protein expression in this mouse model, even though the staining for fibrosis was negative. That told us that there was this underlying hidden fibrosis. Dr. Carolyn Lam: Oh, that is really interesting. And so it is that form of fibrosis that was actually reversed, perhaps, by the HDAC inhibition, and that's what you showed. Would that be accurate to say? Dr. Timothy McKinsey: Yeah. So the HDAC inhibitor really had this profound ability to block that ECM remodeling, the hidden fibrosis, to the point where initially we thought it was an artifact. We thought maybe there was a mix-up of samples. It wasn't a mix up. It's just that the compound, this inhibitor of HDAC enzymatic activity, really has this amazing ability to block the formation of hidden fibrosis. Dr. Carolyn Lam: Oh, wow. Wow, Tom, I really, really loved your editorial where you put all of this in context and talked a little bit about the translational and clinical potential. Could you maybe share your thoughts here? I love the title by the way, Erasing Hidden Fibrosis. Dr. Thomas Gillette: Thanks. Thanks for that. Yeah, first of all, Tim, it was a really great piece of work, and it's actually really exciting because when we think of this diastolic dysfunction, and really it's the development of HFpEF, I think, that a lot of people are... It's the single most critical unmet need in cardiovascular medicine, is the treatment for HFpEF. That diastolic dysfunction, it's really that stiffness that Tim was measuring with his atomic force microscopy and those changes in ECM that really seemed to be critical, at least in that model. Dr. Thomas Gillette: And we know from other models as well that these underlying changes in fibrosis and stiffness, perhaps in the ECM, play a really important role, not only in the diastolic dysfunction, but also if you think about in strain as well, because I know in our models of HFpEF and this mouse model of HFpEF, we have the two-hit model published that Gabrielle, a Allie developed with Dr. Hale in Nature. It's that strain that we could measure that really seems to correlate well with the heart failure phenotype. And so it begs the question, has he caught a very early change in the ECM that's really critical to the development of this pathology? And is there a way that we could detect it early on in patients? Is there a way we could measure that in patients and really get a sense of who's progressing and how they're progressing? Dr. Thomas Gillette: Then there's a second point, and I mentioned a little bit in the editorial, I didn't go into it too deeply, and that is, it's really intriguing what this might mean for the development of the disease, because the matrix not only is involved in stiffness, but it's also a reservoir for growth factors, it helps recruit inflammatory cells, and inflammation plays a huge role in HFpEF. And so it begs the question, how many of those changes may proceed a lot of that pathology as well? Dr. Carolyn Lam: Wow, Tom, I really couldn't agree more. I made a big deal earlier about agreeing with Tim, calling this a diastolic dysfunction model rather than HFpEF, but I completely agree with you that the implications are for the development of HFpEF, and it needed the begs, the question of how many patients actually have this hidden fibrosis? And we know that in patients with HFpEF, there is a stage of advanced fibrosis where we feel patients don't respond to treatment as well. So have we caught an early phase that may be clinically applicable? I really loved the way you worded that. But finally, with Sergio, could you put it all together and what the editors thought of this paper? Why you invited Tom to write this editorial? And perhaps what next steps are? Dr. Sergio Lavandero: Okay, Tim, this is really a fascinating work. I have a long road, because in Italy, you develop the most important new concept. The new concept, the hidden fibrosis. The second important, originally, most of the HDAC inhibitors were developed for other diseases, originally for cancer. So now we have more data that, probably, this compound can apply to other diseases like cardiovascular disease. It was difficult to convince at the beginning some reviewers about the concept of hidden fibrosis, because it's not traditional. But finally, we asked to another expert to, "Okay, why don't you explain, please, this new technique?" For the future, Tim, what do you think? How can we evaluate hidden fibrosis in patients? Dr. Timothy McKinsey: Ideally, and you would have a non-invasive approach to assessing hidden fibrosis in patients. Obviously I know myocardial biopsies could be analyzed using the mass spec approach and atomic force microscopy, but not everyone is going to want to get a myocardial biopsy. So ultimately, we would like to correlate data that we obtain with biopsies, with circulating factors to see if there is a non-invasive surrogate circulating factor that correlates with the existence of hidden fibrosis. I think that would be very powerful clinically. Dr. Sergio Lavandero: What do you think the specificity of this research, because maybe it's too broad? What do you think? Dr. Timothy McKinsey: Yeah, that's a great point. There's a negative impression of general HDAC inhibition, because people just can't believe that you could inhibit a large number of HDAC enzymes throughout the body and not kill someone. But you can. And in our models you can use pretty low doses of these HDAC inhibitors and see efficacy. But obviously, the holy grail in this field would be to identify specific HDAC isoforms that regulate specific disease processes. So we have an active area of investigation where we're trying to tease apart the roles of different HDACs in the heart, with the ultimate goal of finding the HDAC or a subset of HDACs that regulate in fibrosis. Then you could selectively inhibit those and perhaps have a safer drug than a general HDAC inhibitor. Dr. Carolyn Lam: Thank you, once again. This is an amazing discussion and really, really an example of just the kind of papers we love publishing at Circulation. So novel and with such translational potential. Thank you, Tim, again, and Tom and Sergio. Thank you, audience, for joining us today. From Greg and I, you've been listening to Circulation on the Run. Don't forget to tune in again next week. Dr. Greg Hundley: This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors or of the American Heart Association. For more, visit ahajournals.org.
This week our guest is JAR contributor William V. Wenger. The fledgling United States needed major assistance to win its independence from Great Britain, and it came in form of essential loans from some surprising allies. For more information visit www.allthingsliberty.com.
Over the last 20 years, Cristyn has been a key contributor in helping organizations to recruit, train, and retain top talent. Her focus has been on overseeing people operations, upgrading talent and managing performance for optimal results. Cristyn led the Human Resource function at online technology retailer Bluefly. As VP of HR she worked closely with Bluefly’s CEO, and management team regarding the overall people strategy for the business. Her focus was spent on recruiting, talent management, compensation & benefits, culture, and employee relations. Prior to Bluefly, Cristyn held the role of Director of Human Resources for Victorinox Swiss Army overseeing Human Resources for several divisions including: Apparel, Retail, Merchandising, Cutlery, Wenger, and Canada operations. She also led the HR function for luxury bath retailer Waterworks, which included the corporate office and 40 retail stores across the country. Cristyn has also worked for sports and entertainment organizations such as the NY Giants and Madison Square Garden. Cristyn has an MA in Psychology and is a Certified Personal Trainer and Yoga Instructor.
"I don't think that God's goal in the universe is to lessen the amount of sin. I think His primary goal is to increase the amount of connection between Him and His people." Today's guest is therapist Matt Wenger, who works with guys dealing with porn and sex addiction. In the course of that work, he recognized that Christian men have unique challenges in their journey to healing from this addiction. The result of that was the development of Boulder Recovery, which offers a new 14-Day Men's Intensive for Christian guys struggling with porn and sex addiction. Dr. Michael Barta's Trauma-Induced Sex Addiction (TINSA) Model of therapy is integrated with healthy spiritual teaching and practices to promote genuine healing from the attachment wounds and intimacy disorders that drive sexual addiction. The first intensive will be June 19-July 3, 2021. Information can be found at boulderrecovery.com. The music on this podcast is contributed by members of the Samson Society. For more information on this ministry, please visit samsonsociety.com.
We spoke to Keith Costigan, a football legend.Learned about his career in football, on and off the pitch. We spoke about Wenger, Seedorf, Liverpool, rap music, and his love for The Sopranos and The Wire.It was an amazing conversation with one of the best announcers in football.Tap in and enjoy
We return to Denmark for today's episode of Ramble Meets... as Andy sits down with two former Premier League stalwarts in Michael Essien and Johan Djourou!With over 100 international caps and almost forty years in the game between them, Michael and Johan are two of the most experienced members of the exciting project at FC Nordsjælland. They talk about their upbringing in Ghana and Switzerland respectively, playing for the likes of José Mourinho and Arsène Wenger and using their experiences to teach the next generation, with Michael gradually making his way onto the coaches' bench.Search ‘Football Ramble’ on social media to find us, and email us here: email@example.com.***Please take the time to rate and review us on Apple Podcasts or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** See acast.com/privacy for privacy and opt-out information.
Kate, Luke and Vish discuss last night’s action after Chelsea swatted aside what Joe Cole called “a top Championship side” (brave) as well as any common sense around VAR.The heartwarming football news doesn’t stop there: Kinglsey Koman’s been fined for using the wrong supercar, while Lionel Messi has been turned into an AI message bot. Plus, Dinamo Zagreb Zoran Mamić nobly falls on his sword after being sentenced to five years in prison and Arsène Wenger has some dastardly plans straight out of Area 51.Search ‘Football Ramble’ on social media to find us, and email us here: firstname.lastname@example.org.***Please take the time to rate and review us on Apple Podcasts or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** See acast.com/privacy for privacy and opt-out information.